Abstract:【Objective】 To observe the application value of low-dose conbercept in the treatment of retinopathy of prematurity.【Methods】 Totally 80 premature infants with retinopathy admitted to the hospital between January 2019 and January 2020 were enrolled(including AP-ROP, threshold stage ROP and type I ROP before threshold, the diagnosis was in line with anti-VEGF treatment indications). They were divided into control group(38 cases) and low dose group(42 cases) according to the treatment method. The control group was treated with 0.25 mg conbercept, and the low dose group was treated with 0.15 mg conbercept. The total response rates and refractive index in the two groups were recorded. Intraocular pressure of the two groups was compared before and after treatment, and the incidences of complications were recorded. 【Results】 Both doses were effective in the treatment of retinopathy of prematurity, and there was no statistically significant difference in refractive index(P<0.05). Before treatment, there was no statistically significant difference in intraocular pressure between the two groups, but the control group had higher intraocular pressure than the low dose group after treatment(P<0.05). There were no statistically significant differences in the incidences of adverse reactions between the two groups(P>0.05). 【Conclusion】 Low-dose conbercept is effective, safe and reliable in the treatment of retinopathy of prematurity.
